Harte Hanks, Inc. (HHS) Fair Value 2026

HHS · Conglomerates ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.2 /10

32 fundamental signals · 5 models active

Value Trap Risk

LOW (29/100)

Quick Summary — As of 2026-08-27, Harte Hanks, Inc. (HHS) trades at $4.33, versus a $2.73 median fair value across its 5 active models — 36.9% below the current price. QOC: 6.2/10. Value Trap Risk: 29/100 (LOW). 5/13 models active.

Key Facts

Ticker
HHS
Price
$4.33
Quality Score
6.2/10
Value Trap Risk
29/100
Models Active
5/13
Last Updated
Strength: 5 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

Is Harte Hanks, Inc. (HHS) Undervalued or Overvalued in 2026?

According to CirclFi’s 5-model valuation engine, Harte Hanks, Inc. (HHS) appears overvalued as of : the median of 5 independent fair value estimates is $2.73, 36.9% below the current price of $4.33. Estimates range from $0.82 to $7.23. HHS scores 6.2/10 on fundamental quality and 29/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. HHS’s -36.9% gap is wider than that market norm, and the Conglomerates sector median is -20.0%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Harte Hanks, Inc. Stock in 2026? →

What Fair Value Does Each Model Give HHS?

5 Intrinsic Value Models vs. Current Price ($4.33)

Core Models (Unlocked)
Model Fair Value Upside
Ensemble · Low Conviction
 $2.73 -36.9%
Intrinsic · High Conviction
 $0.82 -81.1%
Unlock the Full Matrix

Access 3 additional models including PWERM, Sentiment SOTP, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 5 Models →

Cancel anytime · No contracts · Instant access

What Is HHS's Fair Value Range?

Spread across 5 independent models · $0.82 to $7.23

CirclFi's 5 active models place Harte Hanks, Inc. (HHS) between $0.82 and $7.23 per share, a spread of 235% of the median. The median of that range — $2.73 — is the fair value CirclFi publishes for HHS, against a current price of $4.33.

Low · EROICHigh · PWERM
$0.82median $2.73$7.23
Where the range comes from
Most bearish modelEROIC Spread$0.82
Most bullish modelPWERM$7.23
Model agreement1 bullish · 4 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for HHS. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on HHS, not a CirclFi price target. How each model works →

What Is Harte Hanks, Inc. (HHS) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Harte Hanks, Inc.'s intrinsic value is estimated at $2.73, suggesting the stock is overvalued at its current price of $4.33. With 4 out of 5 models flagging downside (-36.9% vs price), the market may be pricing in unsustainable growth. Model dispersion is worth noting: PWERM targets $7.23 (+66.9%), versus EROIC at $0.82 (-81.1%). This +148.0% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About HHS?

5 of 13 models are currently active for HHS. Of these, 1 model suggests upside while 4 models suggest overvaluation. Taken together, their median fair value for HHS is $2.73 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does HHS Rank in Conglomerates?

Among 31 Conglomerates stocks, HHS ranks #17 by Quality of Company score. CirclFi's QOC score of 6.2/10 evaluates 32 fundamental signals. A score of 6.2 indicates above-average quality.

Within the Conglomerates space, Harte Hanks, Inc. competes in an environment where organic revenue growth often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is HHS a Value Trap?

CirclFi's Value Trap algorithm assigns HHS a score of 29/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

5 of 13 models are active for Harte Hanks, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Harte Hanks, Inc.'s fundamental quality profile registers 6.2/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +148.0% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every HHS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across HHS's 5 active models, average confidence is 33%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Harte Hanks, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Conglomerates Stocks Should You Also Analyze?

10 related Conglomerates stocks with 13-model coverage

CODICompass DiversifiedQOC 6.2TRCTejon Ranch Co.QOC 6.0LGPSLogProstyle Inc.QOC 6.3NNBRNN, Inc.QOC 5.7MATWMatthews International CorporationQOC 6.5FBYDFalcon's Beyond Global, Inc.QOC 5.5FIPFTAI Infrastructure Inc.QOC 5.0VMIValmont Industries, Inc.QOC 9.0MMM3M CompanyQOC 7.5OTTROtter Tail CorporationQOC 8.6

Read investment analysis: CODI · TRC · LGPS · NNBR · MATW · FBYD · FIP · VMI · MMM · OTTR

Which Other Stocks Have a Similar Quality Score to HHS?

7 companies across all industries closest to HHS’s Quality of Company score of 6.2/10.

NMFCNew Mountain Finance CorporationQOC 6.2OMTKOmnitek Engineering Corp.QOC 6.2FLUXFlux Power Holdings, Inc.QOC 6.2GLBSGlobus Maritime LimitedQOC 6.1WXMWF International LimitedQOC 6.2UECUranium Energy Corp.QOC 6.1NVDANVIDIA CorporationQOC 10.0

Read investment analysis: NMFC · OMTK · FLUX · GLBS · WXM · UEC · NVDA

What Else Do Investors Ask About Harte Hanks, Inc.’s Valuation?

What is Harte Hanks, Inc.'s intrinsic value in 2026?

CirclFi puts Harte Hanks, Inc. (HHS)'s intrinsic value at $2.73 — the median of 5 independent model estimates as of 2026-08-27, ranging from $0.82 to $7.23. The Quality of Company score is 6.2/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is HHS overvalued or undervalued right now?

At $4.33, 1 of 5 active models suggest HHS may be undervalued, while 4 indicate potential overvaluation. The median of all 5 fair value estimates is $2.73, 36.9% below the current price of $4.33 — a consensus view that HHS is overvalued. The assessment depends on which methodology best fits Harte Hanks, Inc.'s business model in Conglomerates.

What does a Quality of Company score of 6.2 mean for HHS?

Harte Hanks, Inc.'s QOC of 6.2/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on HHS?

CirclFi analyzes HHS with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 5 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on HHS?

Of the 5 models currently active on HHS, PWERM is the most bullish at $7.23 per share, and EROIC Spread is the most bearish at $0.82. CirclFi's published fair value for HHS is the median of that range, $2.73, not either extreme. The gap between the two ends equals 235% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is HHS a value trap in 2026?

Harte Hanks, Inc.'s Value Trap score is 29/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 5-model valuation engine, Harte Hanks, Inc. (HHS) has a median fair value of $2.73 — 36.9% below the current price of $4.33 — as of 2026-08-27.” Source: circlfi.com/stock/HHS/ · Methodology
Primary sources for this HHS valuation
  • Financial statements: Harte Hanks, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0000045919) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for HHS as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 5 mathematical frameworks give you clarity on HHS.

Unlock All 5 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

3 models hidden for HHS Unlock All 5 — $39/mo